These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 16341288)

  • 61. Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus.
    Kothare PA; Linnebjerg H; Isaka Y; Uenaka K; Yamamura A; Yeo KP; de la Peña A; Teng CH; Mace K; Fineman M; Shigeta H; Sakata Y; Irie S
    J Clin Pharmacol; 2008 Dec; 48(12):1389-99. PubMed ID: 19047364
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4).
    Calara F; Taylor K; Han J; Zabala E; Carr EM; Wintle M; Fineman M
    Clin Ther; 2005 Feb; 27(2):210-5. PubMed ID: 15811484
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A novel antihypertensive effect of exenatide, a GLP-1 agonist.
    Dandona P; Chaudhuri A; Dhindsa S
    Am J Hypertens; 2010 Mar; 23(3):228. PubMed ID: 20154655
    [No Abstract]   [Full Text] [Related]  

  • 64. Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction.
    Mafong DD; Henry RR
    Curr Atheroscler Rep; 2008 Feb; 10(1):55-60. PubMed ID: 18366986
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Exenatide once weekly for the treatment of type 2 diabetes.
    Malone J; Trautmann M; Wilhelm K; Taylor K; Kendall DM
    Expert Opin Investig Drugs; 2009 Mar; 18(3):359-67. PubMed ID: 19243286
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus.
    Gallwitz B
    Drug Saf; 2010 Feb; 33(2):87-100. PubMed ID: 20082536
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Exenatide--an alternative to insulin in the treatment of type 2 diabetes?].
    Kjeldsen R; Sandbaek A
    Ugeskr Laeger; 2008 Sep; 170(39):3039-43. PubMed ID: 18822227
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pharmacology of GLP-1 agonists: describing the therapeutic potential to patients.
    Spellman CW
    J Am Osteopath Assoc; 2011 Feb; 111(2 Suppl 1):eS10-4. PubMed ID: 21389294
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The effects of add-on exenatide to insulin on glycemic variability and hypoglycemia in patients with type 1 diabetes mellitus.
    Jiang LL; Wang SQ; Ding B; Zhu J; Jing T; Ye L; Lee KO; Wu JD; Ma JH
    J Endocrinol Invest; 2018 May; 41(5):539-547. PubMed ID: 29032494
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Clinical application of exenatide in Japanese patients with type 2 diabetes mellitus].
    Toyonaga T; Araki E
    Nihon Rinsho; 2011 May; 69(5):890-4. PubMed ID: 21595277
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects.
    Froud T; Faradji RN; Pileggi A; Messinger S; Baidal DA; Ponte GM; Cure PE; Monroy K; Mendez A; Selvaggi G; Ricordi C; Alejandro R
    Transplantation; 2008 Jul; 86(1):36-45. PubMed ID: 18622276
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [GLP-1 agonists: an overview].
    Hinneburg I
    Med Monatsschr Pharm; 2013 Jul; 36(7):246-51. PubMed ID: 23898602
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus.
    Hoogwerf BJ
    Cleve Clin J Med; 2006 May; 73(5):477-84. PubMed ID: 16708716
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Exenatide effects on gastric emptying rate and the glucose rate of appearance in plasma: A quantitative assessment using an integrative systems pharmacology model.
    Voronova V; Zhudenkov K; Penland RC; Boulton DW; Helmlinger G; Peskov K
    Diabetes Obes Metab; 2018 Aug; 20(8):2034-2038. PubMed ID: 29663628
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Sustained metabolic benefits of ΔTRTX-Ac1, a tarantula venom-derived peptide, when administered together with exenatide in high-fat fed mice.
    Coulter-Parkhill A; Tanday N; Cobice D; McLaughlin CM; McClean S; Gault VA; Irwin N
    Diabetes Obes Metab; 2024 Jan; 26(1):329-338. PubMed ID: 37818589
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Evaluation of the effects of exenatide administration in patients with type 2 diabetes with worsened glycemic control caused by glucocorticoid therapy.
    Matsuo K; Nambu T; Matsuda Y; Kanai Y; Yonemitsu S; Muro S; Oki S
    Intern Med; 2013; 52(1):89-95. PubMed ID: 23291680
    [TBL] [Abstract][Full Text] [Related]  

  • 77. New potential adjuncts to treatment of children with type 1 diabetes mellitus.
    Raman VS; Heptulla RA
    Pediatr Res; 2009 Apr; 65(4):370-4. PubMed ID: 19092720
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Effects of GLP-1 Agonist Exenatide on Cardiac Diastolic Function and Vascular Endothelial Function in Diabetic Patients].
    Wang XH; Han LN; Yu YR; Wang C; Wang B; Wen XR; Huang H; Jing XC
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Jul; 46(4):586-90. PubMed ID: 26480664
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Lixisenatide for the treatment of type 2 diabetes.
    Petersen AB; Knop FK; Christensen M
    Drugs Today (Barc); 2013 Sep; 49(9):537-53. PubMed ID: 24086950
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in Zucker diabetic fatty (ZDF) rats.
    Kwak HH; Shim WS; Hwang S; Son MK; Kim YJ; Kim TH; Yoon ZH; Youn HJ; Lee GI; Kang SH; Shim CK
    Pharm Res; 2009 Nov; 26(11):2504-12. PubMed ID: 19756973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.